Conservative South Wales East AM Mohammad Asghar has called on the Welsh Government to guarantee that a pancreatic cancer drug withdrawn in England remains available on the NHS in Wales.
Speaking in the Senedd on February 9, Mr Asghar said: “Pancreatic cancer has the worst survival rate of the 21 most common cancers in Wales.
“The National Institute for Health and Care Excellence has said that the cancer drug Abraxane should not be funded by the NHS in England due to cost.
“I am seeking assurances from the Welsh Government that pancreatic cancer sufferers will continue to receive this life-extending drug on the NHS in Wales.”
First Minister said the Welsh Government was in discussions with the manufacturers of the drug, and it would remain available to patients in Wales in the interim.